At the last check on Thursday, Vaxcyte Inc.’s (NASDAQ:PCVX) stock was down -$0.49, moving down -1.03 percent to $46.93. The average number of shares traded per day over the past five days has been 576,512 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.44 fall in that time frame. In the last twenty days, the average volume was 485,313, while in the previous 50 days, it was 583,647.
Since last month, PCVX stock rose 0.93%. Shares of the company fell to $45.50 on 08/14/23, the lowest level in the past month. A 52-week high of $54.97 was reached on 06/23/23 after having rallying from a 52-week low of $20.49. Since the beginning of this year, PCVX’s stock price has dropped by -2.13% or -$0.93, and marked a new high 8 times. However, the stock has declined by -14.62% since its 52-week high.
PCVX stock investors should be aware that Vaxcyte Inc. (PCVX) stock had its last reported insider trading activity 219 days ago on Jan 10. Lukatch Heath, the Director of the company, disposed of 315 shares for $46.12 on Jan 10. It resulted in a $14,526 divestment by the insider. Lukatch Heath sold 335 shares at an average price of $43.93 on Dec 12. The insider now owns 3,125 shares following the transaction. On Nov 10, Director Lukatch Heath sold 4,335 shares at $46.13 apiece. The transaction was valued at $199,989.
Financial Health
In the three months ended June 29, Vaxcyte Inc.’s quick ratio stood at 21.80, while its current ratio was 21.80, showing that the company is able to pay off its debt. Based on annual data, PCVX earned $2000.0 in gross profit and brought in $232.26 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Vaxcyte Inc. to report -$0.74 quarterly earnings, the actual figure was -$0.7 per share, beating the consensus estimate by 5.40%. During the quarter, the company generated -$96.59 million in EBITDA. The liabilities of Vaxcyte Inc. were 69.44 million at the end of its most recent quarter ended June 29, and its total debt was $15.21 million. The value of shareholders’ equity is $93.85 million.
Technical Picture
This quick technical analysis looks at Vaxcyte Inc.’s (PCVX) price momentum. With a historical volatility rate of 34.42%, the RSI 9-day stood at 45.23% on 16 August.
With respect to its five-day moving average, the current Vaxcyte Inc. price is down by -0.93% percent or -$0.44. At present, PCVX shares trade -1.76% below its 20-day simple moving average and +24.26% percent above its 100-day simple moving average. However, the stock is currently trading approximately -9.39% below its SMA50 and +8.44% above its SMA200.
Stochastic coefficient K was 33.71% and Stochastic coefficient D was 28.10%, while ATR was 1.81. Given the Stochastic reading of 28.31% for the 14-day period, the RSI (14) reading has been calculated as 46.12%. As of today, the MACD Oscillator reading stands at -0.09, while the 14-day reading stands at -0.74.
Analyst Ratings
TD Cowen launched its rating on Vaxcyte Inc. (NASDAQ: PCVX) to an Outperform in a note to investors on April 18, 2023. Vaxcyte Inc. (PCVX) has been rated Buy by analysts. According to 0 brokerage firms, PCVX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Vaxcyte Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $68.00, the current consensus forecast for the stock is $58.00 – $72.00. Based on these forecasts, analysts predict Vaxcyte Inc. (PCVX) will achieve an average price target of $66.14.
